neoplasms (HDN) constitute a rare disease characterized by aggressive clinical behaviour and a poor prognosis. Tumour cells from HDN are leukaemic counterparts of plasmacytoid dendritic cells (pDCs). Despite increased knowledge of the ontogenetic origin of these tumours, the genetic causes and oncogenic signalling events involved in malignant transformation are still unknown. To delineate novel candidate regions and disease-related genes, we studied nine typical CD4 þ CD56 þ HDN cases using genome-wide high-resolution array comparative genomic hybridization (CGH). Genomic imbalances, which were predominantly losses, were frequently detected. Gross genomic losses or gains involving an entire chromosome were observed in eight cases. The most frequent imbalances were deletions of chromosome 9, chromosome 13 and partial losses affecting 17p or 12p. Combinations of deletions of tumour suppressor genes (TSG), namely RB1, CDKN1B (p27), CDKN2A, (p16 ink4a , p14 arf ) or TP53 (p53), were observed in all cases. These results indicate that deletion events altering G1/S regulation are crucial for HDN oncogenesis. Furthermore, in addition to frequent sporadic gene losses, in one case we observed a 8q24 interstitial deletion that brought MYC closer to miR-30b/miR30d, which may be related to their deregulation. Taken together, these results indicate that in addition to frequent G1/S checkpoint alterations, various genetic events could contribute to the chemoresistance of the tumour.
Introduction
Agranular CD4 þ CD56 þ hematodermic neoplasm (HDN), earlier known as blastic or blastoid natural killer (NK) cell lymphoma, is currently recognized as a distinct entity by the WHO-EORTC classification for cutaneous lymphoma. 1 This rare disease is characterized by aggressive behaviour, commonly involving the skin with solitary or multiple nodules. Most patients rapidly develop bone marrow and peripheral blood involvement together with the involvement of lymph nodes and extranodal sites. 2 Despite an initial response to systemic chemotherapy, most patients relapse, giving a median overall survival of 14 months. Differential diagnosis mainly includes acute myeloid leukaemia (AML), especially myelomonocytic leukaemia with cutaneous involvement, and NK/T cell lymphoma. 3, 4 Tumour cells from CD4 þ CD56 þ HDNs were recently described as the leukaemic counterpart of plasmacytoid dendritic cells (pDCs), an immune cell type that circulates in blood as veiled cells and enters lymph nodes and mucosal sites in response to immune activation. pDCs are continuously produced from haematopoietic stem cells in the bone marrow and differentiate into the DC2 subset of DCs, which are widely distributed in lymphoid and non-lymphoid tissue. Both normal pDCs/DC2 and CD4 þ CD56 þ HDN cells express CD123, HLA-DR and blood DC antigens 2-4 (BDCA-2, BDCA-4), and produce a-interferon in response to inactivated influenza virus. 5 It was recently suggested that only a subset of CD123 þ /HLA-DR þ pDC expresses CD56 and can assume full DC2 effector function upon maturation. 6 Despite the knowledge of this cellular origin, the genetic causes and the oncogenic signalling events that lead to CD4 þ CD56 þ HDN are unknown. Cytogenetic analysis of B40 cases has shown that gross genomic losses predominate, and no specific abnormality was identified. However, six major chromosomal targets, namely chromosome 5q (5q21 and 5q34), chromosome 12p (12p13), chromosome 13q (13q13 and 13q21), chromosome 6q (6q23-ter), chromosome 15q and chromosome 9, were identified. 4, 7 More recently, recurrent deletions of regions of chromosome 4 (4q34), chromosome 9 (9p13-p11 and 9q12-q34) and chromosome 13 (13q12-q31) were reported in five cases using an array-based comparative genomic hybridization (CGH) approach. In spite of a very limited number of cases, some candidate genes and their relationship with gene expression profiles were identified. 8 In this study, it was shown that deletions of several tumour suppressor genes (TSG), including RB1, LATS2, CDC14B, DBC1 and SYK, were effectively related to diminished expression. In contrast, some highly expressed oncogenes, such as HES6, RUNX2 and FLT3, were not associated with an increase in gene copy number. 8 In support of the aim to delineate novel candidate regions and disease-related genes, we studied nine CD4 þ CD56 þ HDN cases using the genome-wide high-resolution array CGH.
Patients and methods

Patient selection and materials
Nine patients with CD4 þ CD56 þ HDN were included in this study. The clinical details of these patients are summarized in Table 1 . Data on patient 1 have been published earlier. 7, 9 Neoplastic cells expressed CD4 and CD56, but were negative for B-cell, T-cell and myelomonocytic markers. However, two cases weakly expressed CD33. Using standard methods, highmolecular-weight DNA was prepared from pre-treatment samples that included frozen cells (n ¼ 6) or fresh cells (n ¼ 3), from peripheral blood (n ¼ 5), bone marrow (n ¼ 3), and lymph node (n ¼ 1). In one case, DNA was obtained from a CD4+ CD56+ cell line (GEN2.2). 10 In the interests of clarity, the GEN2.2 line is referred to as case 1 throughout the manuscript.
Array-based comparative genomic hybridization
Genome-wide analysis of DNA copy number changes was performed using a high-resolution 60-mer oligonucleotidebased microarray that contained B43 000 probes, with an average spatial resolution of 35 kb (Human Genome CGH Array 44B, Agilent Technologies, CA, USA) in eight cases, and a higher resolution microarray containing 240 000 probes (Human Genome CGH Array 244K, Agilent) in one case (case 1). Digestion was performed as recommended by the manufacturer of the arrays. Tumour DNA was labelled with cyanine-5 (Cy5) and reference DNA (pooled normal DNA, Promega, Madison, WI, USA) was labelled with cyanine-3 (Cy3).
Microarray image analysis was performed with Agilent DNA Analytics 4.0 software. Classification as gain or loss was based on identification by the CGH plotter and visual inspection of the log 2 ratios, using z-score and ADM-2 algorithms. Data sets were reviewed for frequently affected chromosomal sites of physiological copy number variations (CNV), by comparison with the database genomic variants included in the software database (which contains more than 15 000 CNVs).
Breakpoint mapping and real-time quantitative reverse-transcription PCR
A particular deletion in case 4 detected by CGH experiment and located within chromosome 8q24 locus delineated by MYC and miR-30b/miR-30d was cloned using a direct PCR approach. (Primer sequences and PCR conditions are available on request.)
The expression of miR-30b/miR-30d, located within the telomeric part of the deletion, was subsequently assessed using TaqMan microRNA expression assays (Applied Biosystem, Foster City, CA, USA) in case 4 and compared with three cases with available tumour RNA. Quantitative reverse-transcriptase PCR (qRT-PCR) was performed using the ABI Prism 7900 HT sequence detection system (Applied Biosystem). RNU48 gene was used as control, as indicated by the manufacturer. Gene expression levels were calculated with the 2 DDCT method by using the endogenous control. In addition, the expression of MYC, located within the centromeric boundary of the deletion, was assessed by qRT-PCR, using the PBGD gene as an endogenous control. Abbreviations: aBMT, allogenic bone marrow transplantation; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; Asp, asparaginase; BM, bone marrow; CHOP, cyclophosphamide, doxorubicin, vincristin, prednisone; CNS, central nervous system; CR, complete remission; LN, lymph nodes; MTX, methotrexate; P, progression; PR, partial response.
Multiplex quantitative PCR assay and comparison with acute myeloid leukaemia Recurrent gene copy number abnormalities involving RB1, CDKN2A, TP53 and CDKN1B were verified by a quantitative genomic PCR approach, namely PCR of short fluorescent fragments (QMPSF), as reported earlier in solid tumours, chronic lymphocytic leukaemia and lymphomas. 11 Briefly, QMPSF is a sensitive method for the detection of genomic deletions or duplications based on the simultaneous amplification of short genomic fragments using dye-labelled primers under quantitative conditions. PCR products were analysed on an ABI Prism310 genetic analyser in the fragment analysis mode, in which both peak heights and areas are proportional to the quantity of template present for each target sequence. The CECR1 and SEMA4F genes were used as references. PCR primer sequences and location are indicated in Supplementary Table 1 . QMPSF was performed to confirm CGH results and to allow comparison of abnormality frequencies for the 11 AML cases with monocytic differentiation (including four AML-4 and seven AML-5 cases). The clinical and cytogenetic features of these are indicated in Supplementary Table 2. DNA was extracted from blood/bone marrow samples containing at least 50% blast cells. Allelic status was used as a score applicable for hierarchical clustering analysis. Biallelic deletion was scored as À2, monoallelic as À1 and germline configuration as þ 1. Clustering was performed using Cluster 3.0 and Tree View software (http://rana.lbl.gov/EisenSoftware.htm).
TP53 mutational status
To investigate the frequency of TP53 mutations, the highly conserved exons 5-8 (central core domain) were screened for mutation, as described earlier in seven cases. 12 
Results
Global genomic aberrations
Genomic imbalances were detected in all cases. Losses were more frequent than gains (Table 2 ). Gross genomic losses or gains involving an entire chromosome were observed in 8/9 cases. The most frequent findings were loss of chromosome 9 (four cases) or chromosome 13 (five cases). The other numerical abnormalities included loss of chromosome 15 (one case), chromosome 6 (one case), or gain of chromosomes 20 (one case) or 21 (three cases). The most frequent partial chromosomal losses affected 5q (four cases), 7p (two cases), 8q (two cases), 9p (two cases), 12p (six cases), 13q (two cases) and 17p (three cases). Other partial chromosomal imbalances sporadically affected 1p (one gain), 2q (one loss) and 3p (one gain) ( Table 2 ). The complete report of genomic aberrations, including cytobands, log 2 probe fluorescence level, P-values, gene/microRNA lists and ideograms, are indicated in Supplementary Table 3 .
Delineation of candidate gene in commonly deleted regions Chromosome 9. Loss of chromosome 9 was the most frequent cytogenetic abnormality. The CDKN2A and CDKN2B genes, located on chromosome 9p21, displayed a monoallelic loss in two cases and a biallelic deletion in four cases. In one case with the CDKN2A homozygous deletion (case number 1), the centromeric breakpoint mapped between the CDKN2A and CDKN2B genes. In another case (case 3), the telomeric breakpoint of the homozygous deletion mapped near miR-31 and the telomeric breakpoint of the monoallelic deletion were located in the vicinity of miR-491 (Figure 1a ).
Chromosome 13. Partial or complete chromosome 13q
deletions were observed in seven cases. The commonly deleted region (CDR) encompassed the 13q13.3-q14.2 locus, which contains B10 known coding genes. In one patient (case 9), a homozygous deletion of 1.4 Mb containing 12 genes included in the CDR was observed. Analysis of probes related to RB1 indicated that the centromeric breakpoint mapped within the RB1 gene and disrupted its coding region (Figure 1b ).
Chromosome 12. Six patients exhibited partial or complete loss of chromosome 12p, which allowed us to define a CDR represented by a 1.9-Mb (10.8-12.7) region on 12p13.2 locus. This CDR contains B15 known coding genes, including the tumour suppressor genes CDKN1B and ETV6. One case displayed a biallelic loss of a 2.6-Mb region that included these two genes. In one case, the breakpoint was located within ETV6 ( Figure 1c ).
Chromosome 17. Three cases harboured a partial or complete loss of chromosome 17p. On the basis of these cases, a CDR was delineated and defined by the telomeric 17p region of 8 Mb that includes TP53. No homozygous deletion of this gene was observed.
Chromosome 5. A 29-Mb CDR (124.8-153.9) was delimited in three cases. This region contains numerous candidate genes, including MSH3 and miRNA coding genes ( Table 2) .
Delineation of candidate genes in sporadic minimal lost and gained genomic regions
Several genomic losses and gains involving a very limited part of the genome were identified in all cases (Table 2 ). In some, sporadic deletions involved well-known TSG, but also suggested the existence of candidate genes at these sites (Table 2) .
Notably, in two cases, deletion breakpoints were closely located to the MYC gene, but its coding region was retained, suggesting that MYC conservation may represent an important genetic event in combination with loss of some TSG (Figure 2) . Furthermore, none of the nine cases displayed any copy loss of MYC.
Involvement of miRNA containing loci in rearranged regions
In addition to well-defined protein coding genes, imbalances that involved regions containing miRNA were observed (Table 2) . However, in comparison with the overall deletion events, deletions involving specifically miRNA coding regions did not occur at a higher frequency (w 2 test, data not shown). One miRNA, located within a defined CDR, namely miR-31 (9p21), displayed a biallelic loss in combination with deletion of CDKN2A. Monoallelic losses implicated either CDR-related miRNA, such as miR16-1, miR-15a (13q13), miR-613 and miR-614 (12p13.2), miR-378, miR-145, miR-143 and miR-584 (5q), or miRNA located in sporadically deleted regions (Table 2) . Furthermore, some breakpoints were located in the vicinity (o1 Mb) of regions containing miRNA (Table 2) . For instance, a 5.6-Mb deletion on chromosome 8q24 moved MYC and miR30b closer together in one case (Figure 2) . The deletion led to PVT1 (55 kb distal to MYC) and ZFAT1 (zinc finger and AT hook CD4 þ CD56 þ haematodermic neoplasm oncogenesis F Jardin et al The deletion disrupts PVT1 and brings ZFAT1/miR-30b into proximity of the MYC locus. MicroRNA (red circles), exons (boxes) and deletion (dashed square with numbering according to NCBI (build 36)) are depicted as indicated. PVT1 gene organization is depicted according to Huppi and colleagues. 13 (c) RT-Q-PCR analysis of miR-30b/miR-30d (white) and MYC (grey) gene expression relative to RNU48 and PBGD, respectively, in four cases. As the range of expression of miR-30b and miR-30d was similar, only the average expression (and s.d.) of the two microRNA is represented. domain containing or ZNF406) genes being placed closer together (Figure 2b ). To determine whether these structural changes were related to gene expression changes of MYC and miR-30b/miR-30d, RQ-PCR experiments were subsequently conducted. The highest level of miR-30b and miR-30d expression was observed in case 4. Furthermore, MYC expression was observed at higher level in case 4 as compared with cases 5, 6 and 8. Together these observations suggest that this deletion may be related to both MYC and miR-30b/miR-30d upregulation (Figure 2c) .
In other cases, breakpoints occurred close (o0.5 Mb) to various miRNA, including miR-15a, miR-31, miR-320 or miR-621 ( Figure 1 and Table 2 ). In case 2, monosomy 9 was incomplete, and an B8-Mb region (9q22.2-q31.1) that contains the let-7 miRNA family cluster was retained.
Comparison of gene copy number abnormalities between CD4 þ CD56 þ HDN and AML QMPSF was performed to confirm the allelic status of TP53, CDKN2A, CDKN1B and RB1 in the nine cases. Concordance between CGH and QMPSF was verified in all cases, confirming gene copy number abnormalities (Figures 3a and b) . As 9/9 cases displayed mono-or biallelic deletions of TP53, CDKN2A/ CDKN2B, RB1 or CDKN1B genes, these data suggest that alteration of the G1/S transition represents a crucial and frequent event in the oncogenic pathways of CD4/CD56 þ HDN. In eight cases, deletion of at least two of these genes was observed (Figure 3a) . In five cases, comparison with 11 AML-4/5 cases using QMPSF indicated that such a genomic patterns is unusual in AML (Figure 3) . These results show that the gene copy number pattern of four well-defined TSG, namely RB1, CDKN2A, CDKN1B and TP53, strongly discriminate between AML and CD4 þ CD56 þ HDN.
TP53 mutation and allelic status
TP53 sequence analysis showed two missense single-base substitutions distributed in seven patients. In 2/3 cases, TP53 missense mutations were associated with allelic loss, indicating a complete loss of p53 function in these cases (Supplementary Table 4 ).
Discussion
The array-based CGH technique used in this study gives an average resolution of 35 kb, allowing the identification of recurring imbalances that are likely to pinpoint regions containing genes that contribute to CD4 þ CD56 þ HDN oncogenesis. Despite a limited number of cases, this study represents, to date, the largest series for this rare disease.
Involvements of well-known TSG, namely RB1, CDKN1B (p27), CDKN2A, (p16 ink4a p14 arf ) or TP53 (p53), all implicated in the G1/S transition control, were observed in all cases. Homozygous deletions of some of these genes, including RB1, CDKN2A or CDKN1B, or a combination of deletions were also detected. Significantly, deletions of these genes have been correlated with poor outcome in several tumour subtypes. This is also likely to be the case in CD4 þ CD56 þ HDN.
Interestingly, combined analysis of array-based CGH data and gene expression profiles has not shown a strict correlation between gene copy number and expression level, but a gene dosage effect for RB1 has been observed in CD4 þ CD56 þ HDNs. 8 These observations indicate that deletion of a gene involved in the G1/S transition pathway that could occur in a pDC or DC2 cell is likely to represent a crucial and early oncogenic step in this disease. As a strong association between classic CD4 þ CD56 þ HDN and myelomonocytic leukaemias has been reported (reviewed in Herling and Jones 6 ), such patterns of TSG loss were unusual in our series of de novo AML, confirming that tumour cells had undergone distinct oncogenic events, as shown earlier by changes in expression levels. 8 The delineation of a consensus genomic region in the subgroup of AML with complex karyotype has shown that TP53 and CDKN1B losses can also be frequent in this neoplasm, but not in combination with RB1 deletion.
14 Such combinations are also infrequent in lymphoid neoplasms, as concomitant loss of CDKN2A, RB1 and TP53 was observed in less than 5% of a large panel of various lymphoid malignancies. 15 It is of note that the heat map obtained from unsupervised analysis using the genomic status of TP53, CDKN1B, CDKN2A and RB1 separate CD4 þ CD56 þ HDNs into two distinct branches (Figure 3) . This dichotomy separates a first group mainly characterized by CDKN2A deletions (6/6) without TP53 copy losses (1/6), whereas the second group is, by contrast, mainly defined by the lack of CDKN2A loss (0/3) and a TP53 loss (2/3). However, taken together, these data indicate that CD4 þ CD56 þ HDNs are characterized by an unusual genomic profile that is defined by alteration of different targets controlling the same pathway (G1/S transition). These observations are in agreement with those reported recently by Dijkman et al. 8 In comparison with this series, our data confirm that recurrent chromosomal alterations involve mainly chromosomes 9 and 13 and delineate a very similar CDR. However, we could not confirm the frequent deletion of chromosomes 4q34.1-4q34.2 or 9p13.2-9p11.2, two regions that did not show altered expression in relation to copy number loss. 8 In addition, we failed to detect the deletion of a large portion (46-134.9 Mb) of chromosome 9q. 8 These differences either likely reflect a degree of genetic heterogeneity within this disease entity or may result from differences in patient selection or technical approaches.
An additional spectrum of sporadic losses smaller than 10 Mb was identified in almost all cases. These deletions involve many genes that were earlier reported to be frequently lost by deletion, mutation or promoter methylation events in various solid tumours and acute leukaemia, such as ETV6 (12p13),
14, [16] [17] [18] [19] [20] [21] [22] [23] [24] These genes are involved in major cellular processes, including DNA repair (MSH3, MSH5, HUS1), cell cycle regulation (HUS1, CDKN2D) and the RAS pathway (NF1). Another gene, IDE (10q32), a putative tumour suppressor insulin degrading enzyme, may play a role as a RB protector by preventing inactivation of RB1.
25 Deletions of the gene may then reinforce alteration of the G1/S RB1 pathway. In addition, the transcription factor E2F1 is a target of MYC that promotes cell cycle progression, suggesting that sustaining MYC expression may also reinforce G1/S progression. 26 However, in contrast with CDKN2A, RB1, CDKN1B or TP53, these genes do not localize in recurrent or overlapping deleted regions, most likely suggesting their involvement in stochastic secondary genetic events.
Our study is the first report that describes genomic aberrations involving miRNA coding genes. Notably, some of these, known to act as TSG, such as miR-16-1 and miR-15a, are implicated in short deletion events. Additional miRNA, such as miR-10b, miR-218 or miR-199a1, also represent candidate genes. For instance, miR-218 appears to be specifically underexpressed during carcinogenesis in cervical carcinomas and miR-199a1 belongs to the most down-regulated miRNA in ovarian cancer, suggesting some tumour suppressor function. 27, 28 However, as miRNA functions are strongly associated with the developmental status of the cell, the role of these miRNA in the CD4 þ CD56 þ HDN setting and the correlation between miRNA expression and their genomic status remains to be determined. A mechanism of deregulation, which likely occurs in some cases, is a direct rearrangement of miRNA genes at the vicinity of genomic breakpoints. These rearrangements, by modifying the genomic context surrounding miRNA, may favour deregulation of both miRNA and junction-partner genes. Interestingly, in one case, a deletion of 5.6 Mb brought the MYC oncogene and miR-30b into close proximity to one another. Our results suggest that this interstitial deletion involving the PVT1 locus, known to contain clusters of breakpoints or retroviral integration sites, that brings MYC near miR-30b/miR-30c may be responsible for an overexpression of these genes. In addition, it has been recently described that a genomic sequence covering the PVT1 gene contains seven miRNAs (Figure 2b ) that are overexpressed in several breast and colon cell lines. 13 Such a rearrangement has been reported earlier in a case of acute pre-B cell leukaemia harbouring a t(8;17), leading to the juxtaposition and deregulation of MYC and miR-142. 29 However, our results need to be interpreted with regard to the inherent limitations of our technical approach, as CGH array does not allow us to detect balanced rearrangements, uniparental disomy or imbalances present in only small subclones.
In conclusion, our study provides new information regarding pathways involved in CD4 þ CD56 þ HDN oncogenesis. Our observations indicate that genes controlling the RB1/E2F pathway are constantly altered by deletion mechanisms, distinguishing this disease from AML4/5. Candidate genes, including various well-defined TSG involved in solid tumours and various miRNA, are also frequently deleted. These multiple losses may explain the frequent occurrence of chemoresistance after initial partial or complete responses to conventional chemotherapy in these patients, as illustrated by the complete loss of TP53 in two cases, in accordance with the Knudson model. As most of these genes have been earlier reported to be down-regulated by promoter methylation, further investigation is warranted to assess their methylation status in combination with expression in the setting of CD4 þ CD56 þ HDN.
